High pancreatic-specific lipase after Velagliflozin (Senvelgo) in cats
156 reports to the FDA describe high pancreatic-specific lipase in cats given Velagliflozin. That is 3.3% of all reports for this medicine, compared with 0.2% across reports for all cat medicines, so it is reported unusually often with this medicine.
156Reports
31%Marked serious
5.1%Recovered
9.6%Died or euthanised
12 daysTypical onset
Sponsored
How soon it started
How the animals did
Problems reported at the same time
Age of the animals
About this medicine
Velagliflozin treats diabetes in cats (oral, an SGLT2 inhibitor).
Products with this ingredient include Senvelgo. The FDA hides brand names in its public data, so these reports cover every product with the same active ingredients.
Questions owners ask
- Can Velagliflozin cause high pancreatic-specific lipase in cats?
- 156 reports link the two, but a report alone does not prove the medicine was the cause: other illnesses, other medicines or coincidence can be involved. Your vet can judge it for your animal.
- How soon after a dose was it reported?
- In half of the reports with dates, it started within 12 days of the first dose.
- What should I do?
- Don't give another dose until you've spoken to your vet, and keep the packaging so you can tell them the product and dose. Your vet can also report it to the FDA (or you can, through the manufacturer or FDA form 1932a).
High pancreatic-specific lipase with similar medicines
- High pancreatic-specific lipase after Bexagliflozin (Bexacat) 111 reports · 2.7% of its reports
- High pancreatic-specific lipase after Insulin 23 reports · 0.6% of its reports
All reported side effects of Velagliflozin in cats · Medicines most reported with high pancreatic-specific lipase